Eiger names industry vet as VP global regulatory affairs
California-based rare diseases specialist Eiger BioPharmaceuticals (Nasdaq: EIGR) today announced the appointment of Mark Mannebach, as vice president of global regulatory affairs.
Dr Mannebach was most recently VP of global regulatory affairs and quality assurance at Charleston Laboratories where he was a member of the executive team and responsible for global regulatory strategy as well as developing technical requirements of supply and quality management.
Just last week, Eiger lured Janssen Biopharma exec Jeysen Yogaratnam to its team as vice president of global hepatitis Delta virus (HDV) clinical development, but in May said David Apelian will step down as its chief operating officer and executive medical officer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze